Phase III TRITON3 trial of Rubraca meets primary endpoint in prostate cancer
Clovis Oncology announced positive top-line data from the Phase III, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca (rucaparib) monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide